DOTTI, KATIA FIORELLA
DOTTI, KATIA FIORELLA
Universita' degli Studi di MILANO
Weighing the prognostic role of hyponatremia in hospitalized patients with metastatic solid tumors: the HYPNOSIS study
2019 G. Fucà, L. Mariani, S. Lo Vullo, G. Galli, R. Berardi, M. Di Nicola, C. Vernieri, D. Morelli, K. Dotti, I. Fiordoliva, S. Rinaldi, C. Gavazzi, F. Pietrantonio, M. Platania, F. de Braud
Dose-Dense Temozolomide in Patients with MGMT-Silenced Chemorefractory Colorectal Cancer
2016 F. Pietrantonio, F. de Braud, M. Milione, C. Maggi, R. Iacovelli, K.F. Dotti, F. Perrone, E. Tamborini, M. Caporale, R. Berenato, G. Leone, A. Pellegrinelli, I. Bossi, F. Festinese, S. Federici, M. Di Bartolomeo
Capecitabine, oxaliplatin and irinotecan in combination, with bevacizumab (COI-B regimen) as first-line treatment of patients with advanced colorectal cancer : an Italian Trials of Medical Oncology phase II study
2015 M. Di Bartolomeo, A. Ciarlo, A. Bertolini, S. Barni, C. Verusio, E. Aitini, F. Pietrantonio, R. Iacovelli, K.F. Dotti, C. Maggi, F. Perrone, E. Bajetta
Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT
2014 M. Di Bartolomeo, F. Pietrantonio, F. Perrone, K.F. Dotti, A. Lampis, C. Bertan, E. Beretta, L. Rimassa, C. Carbone, P. Biondani, R. Passalacqua, S. Pilotti, E. Bajetta
Chronomodulated capecitabine and adjuvant radiation in intermediate-risk to high-risk rectal cancer : a phase II study
2014 E. Bajetta, F. Pietrantonio, R. Buzzoni, E. Ferrario, F. Valvo, L. Mariani, K.F. Dotti, P. Biondani, B. Formisano, A. Gevorgyan, P. Grassi, M. Di Bartolomeo
Circulating biomarkers in advanced colorectal cancer patients randomly assigned to three bevacizumab-based regimens
2014 A. Martinetti, R. Miceli, E. Sottotetti, M. Di Bartolomeo, F. de Braud, A. Gevorgyan, K.F. Dotti, E. Bajetta, M. Campiglio, F. Bianchi, G. Bregni, F. Pietrantonio